Mast Adds New Board Member
This article was originally published in Scrip
Mast Therapeutics has appointed Matthew Pauls to its board of directors. Currently Pauls is president, CEO and on the board of Strongbridge Biopharma PLC. and prior to this he was chief commercial officer of Insmed, Inc. Before this, he was senior vice-president, head of global commercial operations at Shire Pharmaceuticals. Previously, Pauls held senior positions at Bristol-Myers Squibb, in brand management and payor marketing, and at Johnson & Johnson in various US and global commercial roles.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.